Почетна › Многи мијелом › Вашингтон › Seattle
Kliničke studije za Многи мијелом u gradu Seattle, WA
22 studija za Многи мијелом traži učesnike na lokacijama u gradu Seattle i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Fred Hutchinson Cancer Center - Seattle - Eastlake Avenue East /ID# 267940, Seattle
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Тражи се учесникФаза 1
- VA Puget Sound Health Care System, Seattle
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Fred Hutchinson Cancer Center, Seattle
Collection of Tissue Samples for Cancer Research
Тражи се учесникОпсервациона студија
- Fred Hutchinson, Seattle
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1/2
- Swedish Cancer Institute, Seattle
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Тражи се учесникФаза 1/2
- University of Washington, Seattle
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Тражи се учесникФаза 3
- Fred Hutchinson Cancer Research Center, Seattle
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Тражи се учесникФаза 1/2
- Research Site, Seattle
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 2
- Fred Hutchinson Cancer Center, Seattle
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Тражи се учесникФаза 3
- Research Site, Seattle
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Тражи се учесникФаза 2
- University of Washington, Seattle
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Тражи се учесникФаза 2
- Swedish Cancer Institute, Seattle
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Тражи се учесникФаза 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Тражи се учесникФаза 3
- Saint Joseph Medical Center Hematology and Oncology - Silverdale, Silverdale · 17 ми удаљено
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Тражи се учесникФаза 3
- Research Site, Seattle
- Research Site, Seattle
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Тражи се учесникФаза 1/2
- Fred Hutch Cancer Center, Seattle
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Тражи се учесникФаза 3
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- и још 1
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Swedish Medical Center - Seattle /ID# 268052, Seattle
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Swedish Medical Center, Seattle
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Тражи се учесник
- University of Washington, Seattle
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
Тражи се учесник
- University of Washington, Seattle
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
Тражи се учесникОпсервациона студија
- All4Cure, Seattle
Studije za Многи мијелом u drugim gradovima
- New York City, NY59 студија
- Boston, MA45 студија
- Atlanta, GA42 студија
- Houston, TX39 студија
- Durham, NC36 студија
- Nashville, TN31 студија
- Denver, CO26 студија
- St. Louis, MO26 студија
- Rochester, MN25 студија
- Columbus, OH25 студија
- Chicago, IL24 студија
- Milwaukee, WI23 студија
Ostale studije u gradu Seattle
- Немалоклетни карцином плућа55 студија
- Рак (све врсте)48 студија
- Рак простате45 студија
- Akutna mijeloidna leukemija40 студија
- Метастатски карцином39 студија
- Рак дојке37 студија
- Колоректални карцином35 студија
- Рак плућа34 студија
- Рак јајника29 студија
- Рак панкреаса22 студија
- Akutna limfoblastna leukemija22 студија
- Hronična limfocitna leukemija22 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.